{'fraction_non_alphanumeric': 0.03585147247119078, 'fraction_numerical': 0.020486555697823303, 'mean_word_length': 5.462809917355372, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MYELOFIBROSIS: PROGNOSTIC FACTORS AND TREATMENT

Myelofibrosis (MF) is an interesting, if uncommon, myeloproliferative disorder characterized by splenornegaly, a leucoerythroblastic blood picture, distorted and teardrop-shaped red cells, and varying degrees of bone marrow fibrosis. The haemopoietic abnormalities in MF have been shown to arise from a single neoplastic stem cell, with fibrosis as a secondary effect (Jacobson et al, 1978: Castro-Malaspina et al, 1982). Bone marrow fibrosis may be seen in many diseases (McCarthy, 198 5) whereas the clonal miyeloproliferative disorder MF is a specific syndrome. Patients with MF are known to have a variable clinical course (Ward & Block, 1971 ), which is but one of the reasons for the controversies surrounding their treatment.